. Findings of chronic radiation laryngitis consist of vocal fold erythema and edema; hypervascularity; thick secretions alongthe vocal folds, supraglottis, and posterior hypopharynx; pooling within the piriform sinuses; and diffuse edema.
A 40-year-old man with a remote history of head and neck radiation for Hodgkin lymphoma presented with dysphonia, voice fatigue, and productive cough . of 1 week's duration. Strobovideolaryngoscopy revealed diffuse erythema, increased mucus viscosity, bilateral vocal fold varicosities, and bilateral vocal fold stiffness and scars. His symptoms and examination findings suggested acute laryngitis superimposed on chronic radiation laryngitis (figures 1 and 2).
Acute laryngitis has a variety of causes, including viral, bacterial, or fungal infection and phonotrauma, among others. Acute viral laryngitis has an unknown incidence as it is often found in conjunction with upper respiratory infections and is not reported well in the literature. It is thought to be caused by the same viruses that cause the common cold (rhinovirus, coronavirus).
In acute laryngitis, inflammation and edema lead to impaired vocal fold vibration. Patients typically complain of a hoarse voice, increased phonation effort, and decreased projection. Symptoms can last up to 2 weeks, and treatment is usually supportive with vocal rest, hydration, and mucolytics.' In severe cases, corticosteroids, antibiotic prophylaxis (controversial), and proton pump inhibitors may be used. Acute bacterial laryngitis may involve the vocal folds or extend to the trachea or supraglottic structures.' Fungal laryngitis is much less common than viral or bacterial laryngitis and usually is associated with immunocompromise. Examination findings include hyperplastic white lesions and hyperemia when Candida is involved. Fungal laryngitis is treated with antifungal medications.
Head and neck radiation therapy causes acute and 
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